NBIX:BMV
Neurocrine Biosciences, Inc
MX$3,154.07
0.00%
(0.00) 1D
Jul 29, 7:55:17 AM GMT-6 · MXN
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Mkt. cap
16.77B
Avg. vol.
42.00
Volume
0.00
52-wk high
MX$3,154.07
52-wk low
MX$2,520.84
No. of employees
2K
Mkt. cap
16.77B
Avg. vol.
42.00
Volume
0.00
52-wk high
MX$3,154.07
52-wk low
MX$2,520.84
No. of employees
2K
News stories
From sources across the web
Simply Wall St
·
2 days ago
Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus
Yahoo Finance
·
2 days ago
Neurocrine Biosciences Q2 Earnings Call Highlights
Stock Titan
·
2 days ago
Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com
AI content may include mistakes. Learn more